The potential of targeting SLAMF7 has already been shown by the clinical activity of elotuzumab, a SLAMF7-specific monoclonal antibody, in combination with IMiDs and dexamethasone in patients with relapsed/refractory MM (RRMM).17, 19 In addition, autologous SLAMF7-specific CAR T-cells demonstrated substantial anti-MM activity in preclinical models.1620, 22 However, the use of allogeneic SLAMF7-specific CAR T cells for MM treatment has not been explored in a preclinical setting using patient samples. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.